Entera Bio Submits Streamlined Phase 3 Protocol to Initiate Registrational Program for EB613 in Postmenopausal Women with Osteoporosis - Entera Bio (NASDAQ:ENTX)

Core Viewpoint - Entera Bio Ltd. has submitted a streamlined Phase 3 protocol to the FDA for EB613, an oral anabolic treatment for postmenopausal women with osteoporosis, aiming for faster patient access and potential commercialization [6][9]. Company Overview - Entera Bio is focused on developing oral peptide and protein replacement therapies, leveraging its proprietary N-Tab® technology platform [11]. - The company's lead product, EB613, is the first oral anabolic treatment for osteoporosis, designed to be taken once daily [11]. Clinical Development - The Phase 3 study will evaluate the percentage change in total hip bone mineral density (BMD) from baseline to 12 months, with a target enrollment of 750 women [8]. - Topline data is expected in the second half of 2028, which is approximately one year earlier than previously anticipated [2][3]. - The study is designed to demonstrate increases in total hip BMD comparable to those reported for Forteo® at 12 months, which is associated with a 60% to 80% relative reduction in vertebral fracture risk [8]. Regulatory Submission - Entera has submitted a clinical amendment to the FDA, including a statistical analysis plan and an open-label extension study synopsis [6][7]. - The open-label extension study will randomize participants to receive EB613 for either 12 or 24 months or transition to a standard anti-resorptive agent [3]. Market Context - Osteoporosis is a significant public health issue, with over 2 million fractures annually in the US, and the total medical cost of osteoporotic fractures projected to rise from $57 billion in 2018 to $95 billion by 2040 [10]. - Postmenopausal women are particularly at risk, with one in three women suffering an osteoporosis-related fracture after age 50 [10]. Product Efficacy - EB613 has shown rapid dose-proportional increases in bone formation markers and significant increases in lumbar spine, total hip, and femoral neck BMD in a previous Phase 2 study [9][11]. - The product aims to democratize access to anabolic treatment for osteoporosis, addressing a significant unmet medical need [9].